Accéder directement au contenu Accéder directement à la navigation
Article dans une revue

Monoclonal antibodies: also for dermatologists!

Abstract : Therapeutic monoclonal antibodies are henceforth commonly used in the management of psoriasis but have been also used more recently in chronic spontaneous urticaria and atopic dermatitis. Three examples are developed herein: dupilumab, omalizumab and lanadelumab. The specificity of their mechanism of action results from a better understanding of the inflammatory pathways in these chronic diseases, which previously shared either the same targeted topical or systemic treatments. However, their high costs should be put into perspective with the epidemiology, the precise evaluation of the severity, the optimization of first line treatments and the long-term benefit/risk ratio.
Liste complète des métadonnées
Contributeur : Nathalie Salvy-Cordoba <>
Soumis le : vendredi 27 mars 2020 - 10:59:43
Dernière modification le : vendredi 15 mai 2020 - 12:22:08

Lien texte intégral




Aurélie Du-Thanh, Bernard Guillot. Monoclonal antibodies: also for dermatologists!. médecine/sciences, EDP Sciences, 2019, 35 (12), pp.1017-1021. ⟨10.1051/medsci/2019201⟩. ⟨hal-02521031⟩



Consultations de la notice